{
    "clinical_study": {
        "@rank": "99333", 
        "arm_group": {
            "arm_group_label": "Phase I Dose Escalation / Phase II Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and activity of gemcitabine plus\n      trastuzumab and pertuzumab in patients with metastatic human epidermal growth factor\n      receptor 2 (HER2)+ breast cancer who have progressed on at least one prior line of\n      chemotherapy plus HER2 targeted agent such as T-DM1, trastuzumab, or lapatinib."
        }, 
        "brief_title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult males or females (aged 18 or older) with histologically confirmed, metastatic\n             human epidermal growth factor receptor 2 (HER2)+ (by  immunohistochemistry [IHC] 3+\n             or fluorescence in situ hydridization (FISH) ratio \u2265 2.0) breast cancer\n\n          -  Have progressed on at least one prior line of chemotherapy plus HER2 directed therapy\n             such as trastuzumab and/or pertuzumab in the metastatic setting. T-DM1 would count as\n             a line of therapy and patients previously treated with T-DM1 are eligible.\n\n          -  Have not been treated with gemcitabine in the metastatic setting\n\n          -  Measurable disease per Response Evaluation in Solid Tumors (RECIST) 1.1 criteria\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 2\u2264\n\n          -  Left Ventricular Ejection Fraction (LVEF) \u2265 50% at baseline as determined by either\n             echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)\n\n          -  Adequate bone marrow function as indicated by the following:  absolute neutrophil\n             count (ANC) >1500/\u00b5L; Platelets \u2265100,000/\u00b5L; Hemoglobin >10 g/dL\n\n          -  Adequate renal function, as indicated by creatinine \u22641.5x upper limit of normal (ULN)\n\n          -  Adequate liver function, as indicated by bilirubin \u22641.5x ULN, aspartic transaminase\n             (AST) or alanine transaminase (ALT) <2x ULN unless related to metastatic breast\n             cancer to the liver (in which case AST/ALT < 5x ULN is allowed).\n\n          -  Signed informed consent\n\n          -  Adequate birth control in sexually active women of childbearing potential\n\n        Exclusion Criteria:\n\n          -  Active uncontrolled infection or major concurrent illness which in the opinion of the\n             investigator would render the participant unsafe to proceed with the study\n\n          -  Uncontrolled central nervous system (CNS) metastases. Treated, non-progressing CNS\n             disease (documented by brain magnetic resonance imaging [MRI]) off corticosteroids\n             for at least 1 month potential participants are eligible.\n\n          -  Women who are pregnant or lactating\n\n          -  Prior chemotherapy within the last 3 weeks (last 6 weeks for nitrosureas/mitomycin)\n\n          -  Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator\n             lesion (unless objective disease recurrence or progression within the radiation\n             portal has been documented since completion of radiation)\n\n          -  Other concomitant active malignancies\n\n          -  History of significant cardiac disease, cardiac risk factors or uncontrolled\n             arrhythmias\n\n          -  Ejection fraction <50% or below the lower limit of the institutional normal range,\n             whichever is lower\n\n          -  Hypersensitivity to any of the study medications\n\n          -  Untreated psychiatric conditions preventing informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139358", 
            "org_study_id": "MCC-17656", 
            "secondary_id": "ML28939"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase I Dose Escalation / Phase II Treatment", 
                "description": "The phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000mg/m2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850mg/m2) IV D1,8 q21 days.  The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "GEMZAR\u00ae"
            }, 
            {
                "arm_group_label": "Phase I Dose Escalation / Phase II Treatment", 
                "description": "Trastuzumab will be given using an 8mg/kg loading dose on cycle one, day one (C1D1), followed by 6mg/kg IV on subsequent cycles every (q) 21 days.", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin\u00ae"
            }, 
            {
                "arm_group_label": "Phase I Dose Escalation / Phase II Treatment", 
                "description": "Pertuzumab will be given using an 840mg IV loading dose on C1D1, followed by 420mg IV on subsequent cycles q21 days.", 
                "intervention_name": "Pertuzumab", 
                "intervention_type": "Drug", 
                "other_name": "PERJETA\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast - Female", 
            "Metastatic", 
            "HER2+"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "dawn.carney@moffitt.org", 
                "last_name": "Dawn Carney", 
                "phone": "813-745-1807"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Hatem Soliman, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Hyo Han, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Roohi Ismail-Khan, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Loretta Loftus, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Susan Minton, D.O.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Hatem Soliman, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Establishing the recommended phase II dose for the combination of gemcitabine+trastuzumab+pertuzumab with safety data described using Common Terminology Criteria for Adverse Events (CTCAE) 4.0 terminology. Any patient who receives any dose of the study treatment will be evaluated for the safety/toxicity endpoints in the trial.", 
                "measure": "Phase I: Recommended Phase II Dose", 
                "safety_issue": "Yes", 
                "time_frame": "Upon Determination of Phase II Dose - Approximately 6 Months"
            }, 
            {
                "description": "Objective Response Rate: Complete Response (CR) + Partial Response (PR) using Response Evaluation in Solid Tumors (RECIST) 1.1 criteria for the combination of gemcitabine+trastuzumab+pertuzumab at the recommended phase II dose. Any patient who receives any dose of the study treatment will be evaluated for the safety/toxicity endpoints in the trial. To be considered evaluable for the primary efficacy endpoint (ORR) the patient must undergo two treatment cycles followed by a response scan. CR: Disappearance of all evidence of tumor for at least two cycles of therapy. Tumor markers must be normal. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking a reference the baseline sum longest diameter.", 
                "measure": "Phase II: Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Median progression free survival (in months) for all patients evaluable for response. The time-to-event data will be summarized using Kaplan-Meir curve method for all patients who are evaluable for the ORR endpoint. Progressive disease (PD): At least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the beginning of treatment or the appearance of one or more new lesions.", 
            "measure": "Phase II: Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 Months"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}